Agyany Pharma

About

Offices

Q&A

What is Agyany Pharma's primary focus in drug development?

Agyany Pharma is developing treatments for Parkinson's disease, specifically focusing on ambroxol as a pharmacological chaperon for GBA1-related Parkinson's.

When was Agyany Pharma founded?

Agyany Pharma was founded in 2026.

What is the total amount of funding Agyany Pharma has raised through its Seed and A Rounds?

Agyany Pharma has raised a total of $46,500,000 through its Seed and A Rounds.

When did Agyany Pharma complete its Seed funding round and how much was raised?

Agyany Pharma completed a Seed funding round in February 2019, raising $8,500,000.

When did Agyany Pharma complete its Series A funding round and how much was raised?

Agyany Pharma completed an A Round in June 2020, raising $38,000,000.

Who are the co-founders of Agyany Pharma?

The co-founders of Agyany Pharma are Prof. Dr. Arndt Rolfs and Prof. Dr. Ari Zimran.

Who is the current Chief Executive Officer of Agyany Pharma?

Sivan Frank was appointed Chief Executive Officer of Agyany Pharma in June 2026.

What is Agyany Pharma's strategy for drug development?

Agyany Pharma focuses on repurposing existing generic drugs, such as ambroxol, to target the genetic and molecular drivers of Parkinson's disease.

Team · 8

Prof. Dr. Arndt Rolfs

Founder · Co-Founder and Chairman

Prof. Dr. Ari Zimran

Founder · Co-Founder and Chief Medical Officer

Sivan Frank

Chief Executive Officer

Dr. Aliaksandr Skrahin

Sr. Medical Director

Liana Babchenko Springer

Head of Clinical Trials

Jonathan Arnon

Legal Counsellor

Prof. Mia Horowitz

Staff member

Prof. Dr. Sharon Hassin

Staff member

Sectors & technology